367,702 Shares in Eli Lilly and Company $LLY Purchased by Align Financial LLC

Align Financial LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, HoldingsChannel reports. The fund acquired 367,702 shares of the company’s stock, valued at approximately $36,770,000.

Several other large investors also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP boosted its stake in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the period. Finally, Miller Global Investments LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its neuroscience and pain pipeline by acquiring 4E Therapeutics, a move that could add a non-opioid chronic pain opportunity and diversify growth beyond obesity drugs. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also continues to advance multiple clinical programs, including new studies in Alzheimer’s, neurology, psoriasis, and pain, reinforcing expectations that Lilly can keep building future revenue streams. Lilly Expands Donanemab Ambitions With New Lewy Body Dementia Trial
• Positive Sentiment: Separately, commentary from Jim Cramer urging investors to stay in the stock may have helped sentiment around Lilly’s long-term growth story. Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”
• Neutral Sentiment: Johnson & Johnson’s decision to stay out of obesity drugs is a reminder that Lilly’s blockbuster GLP-1 franchise remains a major competitive advantage, but it does not directly change Lilly’s near-term fundamentals. J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030
• Negative Sentiment: The biggest drag is Lilly’s decision to cut its planned Germany investment in half, citing European drug-pricing reforms that could hurt future R&D and manufacturing economics. That raises concern about international margins and capital allocation. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
• Negative Sentiment: Broader reporting on big pharma pressure tactics in Europe keeps regulatory and pricing risk in focus for Lilly and other drugmakers, which may weigh on investor sentiment if pricing fights escalate. Big pharma taps UK playbook to pressure Europe on drug prices

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research note on Tuesday, May 26th. Finally, HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,111.43 on Thursday. The company has a market cap of $1.05 trillion, a PE ratio of 39.48, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a 50-day moving average price of $1,009.79 and a 200-day moving average price of $1,016.67. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a $1.73 dividend. The ex-dividend date was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.